Windtree Therapeutics, Inc. (WINT)
| Market Cap | 13.50K -99.5% |
| Revenue (ttm) | n/a |
| Net Income | -48.83M |
| EPS | -5.90 |
| Shares Out | 44.99M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,050 |
| Open | 0.0003 |
| Previous Close | 0.0003 |
| Day's Range | 0.0003 - 0.0003 |
| 52-Week Range | 0.0001 - 0.1900 |
| Beta | 1.60 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 18, 2026 |
About Windtree Therapeutics
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trials to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant for the... [Read more]
Financial Performance
Financial StatementsNews
TransCode Therapeutics Announces Leadership Transition
Tom Fitzgerald, Chief Financial Officer, Announces his Retirement John Tattory, to become Interim Chief Financial Officer BOSTON, Sept. 10, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: R...
CommLoan Achieves Nationwide Regulatory Approval Across All 50 States
Company plans reverse merger with Windtree Therapeutics as it expands its AI-powered commercial lending marketplace SCOTTSDALE, Ariz., March 17, 2026 /PRNewswire/ -- CommLoan, a commercial real estate...
Windtree signs agreement for sale of cardiovascular drug candidates to Seismic
Windtree Therapeutics (WINT) announced that it has signed an agreement for the sale of its cardiovascular drug candidates to Seismic Pharmaceutical, a private investment group based in North Carolina,...
Windtree announces it has signed a letter of intent to acquire CommLoan
Windtree Therapeutics (WINT) announced that it has signed a letter of intent to acquire CommLoan, a commercial tech finance company. CommLoan will retain key employees and become a subsidiary of…
Windtree Therapeutics Quarterly report: Q3 2025
Windtree Therapeutics has published its Q3 2025 quarterly earnings report on November 19, 2025.
Windtree may receive license agreement payments for renewed development work
Windtree Therapeutics (WINT) announced that it may receive license agreement payments from its licensee for renewed development work in the Company’s licensed acute pulmonary treatments. The amended a...
Windtree Therapeutics announces patents allowed in Canada, Mexico
Windtree Therapeutics (WINT) announced that acute heart failure patents are allowed in Canada and Mexico. Additionally, the next generation pure SERCA2a activator patent for heart failure was granted ...
Windtree Therapeutics Announces It Will Receive $7.5 Million In Cash and Securities from the Recently Executed Termination Agreement with an Environmental Services Company
Windtree and TESI signed a letter of intent for a combination of cash and securities of TESI to be paid to Windtree The companies were engaged in a potential environmental services deal for Windtree t...
Windtree Therapeutics to receive $7.5M in cash, securities
Windtree Therapeutics (WINT) announced that it has signed a letter of intent with TESI, an environmental services company, and Windtree will receive $7.5 million in cash and TESI securities. The…
Windtree Therapeutics Registration statement: Registration Filing
Windtree Therapeutics filed a registration statement on October 24, 2025, providing details about a securities offering with the SEC.
Windtree Therapeutics stockholders approve key proposals
Windtree Therapeutics (WINT) announced that key proposals for its corporate strategy were approved at the Special Stockholder Meeting on August 28, 2025. The proxy voting reached a quorum prior to…
Windtree Therapeutics Quarterly report: Q2 2025
Windtree Therapeutics has published its Q2 2025 quarterly earnings report on August 19, 2025.
Windtree Therapeutics announces istaroxime chosen for presentation at HFSA
Windtree Therapeutics (WINT) announced that istaroxime was chosen for a presentation entitled, “Safety and Efficacy of intravenous administration of istaroxime for 48 hours in patients with SCAI Stage...
Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025
Presentation will be the interim data from the Phase 2 study of istaroxime in SEISMiC C - Cardiogenic Shock SCAI Stage C
Windtree Therapeutics Proxy statement: Proxy Filing
Windtree Therapeutics filed a proxy statement on August 8, 2025, providing details for shareholder voting and corporate governance matters.
Windtree announces results of interim analysis of SEISMiC Phase 2 study
Windtree Therapeutics (WINT) has performed a planned interim analysis of the SEISMiC C Phase 2 study data evaluating istaroxime in SCAI Stage C cardiogenic shock which showed istaroxime had a…
Windtree Therapeutics Proxy statement: Proxy Filing
Windtree Therapeutics filed a proxy statement on July 30, 2025, providing details for shareholder voting and corporate governance matters.
Windtree Therapeutics announces reduction of Preferred Series C, D shares
Windtree Therapeutics (WINT) announced large reductions in outstanding shares of its preferred series C and D shares. Only 19 preferred series C shares remain. The majority of the Company’s Series…
Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption
Investors choose to redeem or convert the majority of Series C and Series D Preferred 99% of outstanding preferred series C shares are redeemed or converted and preferred series D reduced 68.5% in out...
Windtree enters into common stock purchase agreement for up to $500M
Windtree Therapeutics (WINT) announced it has entered into a Common Stock Purchase Agreement for up to $500M to establish an equity line of credit, ELOC, and bolster its BNB cryptocurrency…
Windtree Therapeutics Announces Up To $520 Million in New Funding to Amplify BNB Cryptocurrency Treasury Strategy
Up to $700 Million Committed to BNB Acquisitions, Reinforcing Innovative Crypto Treasury Strategy Ninety Nine Percent of the proceeds from both issuances to be used to buy BNB WARRINGTON, Pa., July 24...
Windtree Therapeutics, Kraken announce strategic partnership
Windtree Therapeutics (WINT) announces a strategic partnership with Kraken to provide custody, trading, and over-the-counter, OTC, services for Windtree’s BNB Crypto Treasury Strategy. The parties hav...
Windtree Therapeutics to launch BNB crypto treasury strategy
Windtree Therapeutics (WINT) has entered into a $60M securities purchase agreement led by Build and Build Corp, with the potential for up to an additional $140M in gross proceeds in…
Windtree To Launch BNB Crypto Treasury Strategy With Agreement For $60 Million Investment Led By Build And Build Corp. With Up To $140 Million More In Follow On Subscriptions
Windtree expected to become a leader and the first NASDAQ-listed company offering direct exposure to the Binance Smart Chain Ecosystem (BNB) Windtree expected to become a leader and the first NASDAQ-l...
Windtree Therapeutics Registration statement: Registration Filing
Windtree Therapeutics filed a registration statement on July 10, 2025, providing details about a securities offering with the SEC.